Peter Kolchinsky portfolio, Q4 2024
RA Capital Management · 13F for the quarter ending Dec 31, 2024
For Q4 2024, RA Capital Management reported $7.5B across 89 US-listed positions, led by ASND (18.5%), PCVX (9.5%) and JANX (7.4%). Compared with its filing for Q3 2024, Peter Kolchinsky opened 17 new positions, added to 9, reduced 16 and sold out of 9; 47 positions did not change.
The largest purchase was a new position in SEPN ($160.2M); the largest sale, the sale of the whole position in BIIB ($229.6M).
Key facts
- 13F portfolio value
- $7.5BQ4 2024
- Positions
- 89
- Largest holding
- ASND 18.5%
- New positions
- 17
- Sold out
- 9
- Filed
- Feb 14, 2025
Holdings as of (Q4 2024), filed with the SEC on . Changes are measured against the filing for Sep 30, 2024. Every tracked investor's Q4 2024 13F.
Bought and sold in Q4 2024
| Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|
| Biogen IncBIIB | ▼ Sold out | −1.18M | $229.6M | 3.06% |
| Septerna IncSEPN | ▲ New | +7M | $160.2M | 2.13% |
Verona Pharma Plcno ticker on file | ▼ Reduced 65% | −3.24M | $150.6M | 2.00% |
| SPDR Series TrustXBI | ▲ New | +1.23M | $110.6M | 1.47% |
Arcellx Incno ticker on file | ▲ Added 51% | +935.85K | $71.8M | 0.96% |
| Janux Therapeutics IncJANX | ▲ Added 13% | +1.2M | $64.2M | 0.86% |
| Evolent Health IncEVH | ▼ Reduced 58% | −4.94M | $55.5M | 0.74% |
| Ascendis Pharma A/SASND | ▲ Added 4.1% | +402.32K | $55.4M | 0.74% |
| CG Oncology IncCGON | ▼ Sold out | −1.4M | $52.7M | 0.70% |
| Recursion Pharmaceuticals IncRXRX | ▼ Reduced 50% | −7.66M | $51.8M | 0.69% |
| 10X Genomics IncTXG | ▲ New | +3.28M | $47.1M | 0.63% |
| Kura Oncology IncKURA | ▲ New | +4.45M | $38.8M | 0.52% |
| Zai Lab LtdZLAB | ▲ New | +1.3M | $33.9M | 0.45% |
Day One Biopharmaceuticalsno ticker on file | ▼ Reduced 27% | −2.12M | $26.8M | 0.36% |
| Nurix Therapeutics IncNRIX | ▲ New | +1.33M | $25.1M | 0.33% |
| Alto Neuroscience IncANRO | ▼ Sold out | −2.08M | $23.7M | 0.32% |
| Eyepoint Pharmaceuticals IncEYPT | ▲ New | +3.18M | $23.7M | 0.32% |
| Ceribell IncCBLL | ▲ New | +824.58K | $21.3M | 0.28% |
| Newamsterdam Pharma CompanyNAMS | ▲ Added 9.7% | +781K | $20.1M | 0.27% |
| Travere Therapeutics IncTVTX | ▲ New | +1.15M | $20M | 0.27% |
| Vor Biopharma IncVOR | ▲ Added 74% | +16.9M | $18.8M | 0.25% |
| Alector IncALEC | ▲ New | +9.7M | $18.3M | 0.24% |
Nuvalent Incno ticker on file | ▼ Sold out | −176.28K | $18M | 0.24% |
Apogee Therapeutics Incno ticker on file | ▼ Reduced 20% | −392.37K | $17.8M | 0.24% |
| Bright Minds Biosciences IncDRUG | ▲ New | +460.83K | $16.6M | 0.22% |
| Bicycle Therapeutics PlcBCYC | ▼ Reduced 51% | −1.16M | $16.2M | 0.22% |
| Eledon Pharmaceuticals IncELDN | ▲ New | +3.57M | $14.7M | 0.20% |
| Tenaya Therapeutics IncTNYA | ▼ Sold out | −6.98M | $13.5M | 0.18% |
| Cervomed IncCRVO | ▼ Sold out | −817.12K | $11.9M | 0.16% |
| Aclaris Therapeutics IncACRS | ▲ New | +4.67M | $11.6M | 0.15% |
| Monopar Therapeutics IncMNPR | ▲ New | +511.21K | $11.2M | 0.15% |
Cidara Therapeutics Incno ticker on file | ▲ Added 55% | +389.72K | $10.5M | 0.14% |
| Structure Therapeutics IncGPCR | ▼ Reduced 20% | −379.35K | $10.3M | 0.14% |
| Dianthus Therapeutics IncDNTH | ▼ Reduced 20% | −466.6K | $10.2M | 0.14% |
Iteos Therapeutics Incno ticker on file | ▼ Reduced 34% | −1.09M | $8.4M | 0.11% |
| Geron CorpGERN | ▼ Reduced 7.1% | −2.28M | $8.1M | 0.11% |
| Protara Therapeutics IncTARA | ▲ Added 79% | +1.5M | $7.9M | 0.11% |
| RxSight IncRXST | ▼ Reduced 4.4% | −173.81K | $6M | 0.08% |
| Enanta Pharmaceuticals IncENTA | ▲ New | +1.04M | $6M | 0.08% |
| Bioage Labs IncBIOA | ▼ Reduced 41% | −900K | $5.2M | 0.07% |
| Enliven Therapeutics IncELVN | ▼ Reduced 20% | −212.25K | $4.8M | 0.06% |
| Adagio Medical Holdings IncADGM | ▼ Sold out | −1.33M | $3.4M | 0.05% |
Third Harmonic Bio Incno ticker on file | ▼ Reduced 25% | −320.21K | $3.3M | 0.04% |
| Tyra Biosciences IncTYRA | ▲ Added 2.1% | +220.68K | $3.1M | 0.04% |
| 4D Molecular TherapeuticsFDMT | ▼ Reduced 10% | −535K | $3M | 0.04% |
| Metagenomi IncMGX | ▼ Sold out | −1.31M | $2.8M | 0.04% |
| AN2 Therapeutics IncANTX | ▼ Sold out | −2M | $2.1M | 0.03% |
Allakos Incno ticker on file | ▲ New | +1.13M | $1.4M | 0.02% |
| Scholar Rock Holding CorpSRRK | ▲ New | +17.62K | $761.4K | 0.01% |
Regulus Therapeutics Incno ticker on file | ▼ Reduced 56% | −429.99K | $679.4K | 0.01% |
Scilex Holding Cono ticker on file | ▲ Added 297% | +775.04K | $330.5K | 0.00% |
Holdings at the quarter's end
| # | Stock | Sector | Share of portfolio | Value | Shares | Reported price | Held | Since Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| 1 | Ascendis Pharma A/SASND · SPONSORED ADR | Health Care | 18.5% | $1.4B | 10.11M | $137.67 | 3+ qtrs | ▲ Added 4.1% |
| 2 | Vaxcyte IncPCVX | Health Care | 9.47% | $711.3M | 8.69M | $81.86 | 3+ qtrs | No change |
| 3 | Janux Therapeutics IncJANX | — | 7.39% | $555M | 10.37M | $53.54 | 3+ qtrs | ▲ Added 13% |
| 4 | Rhythm Pharmaceuticals IncRYTM | Health Care | 4.53% | $340.6M | 6.08M | $55.98 | 3+ qtrs | No change |
| 5 | Legend Biotech CorpLEGN · SH | Health Care | 3.25% | $244.3M | 7.51M | $32.54 | 3+ qtrs | No change |
| 6 | Edgewise Therapeutics IncEWTX | Health Care | 3.17% | $237.9M | 8.91M | $26.70 | 3+ qtrs | No change |
| 7 | Newamsterdam Pharma CompanyNAMS | — | 3.03% | $227.3M | 8.85M | $25.70 | 3+ qtrs | ▲ Added 9.7% |
| 8 | Wave Life Sciences LtdWVE | — | 3.00% | $225.2M | 18.2M | $12.37 | 3+ qtrs | No change |
| 9 | Arcellx Incno ticker on file · SH | — | 2.85% | $213.8M | 2.79M | $76.69 | 3+ qtrs | ▲ Added 51% |
| 10 | Avidity Biosciences Incno ticker on file · SH | — | 2.44% | $183.2M | 6.3M | $29.08 | 3+ qtrs | No change |
| 11 | Septerna IncSEPN | — | 2.13% | $160.2M | 7M | $22.90 | 1 qtr | New |
| 12 | Dyne Therapeutics IncDYN · SH | — | 2.00% | $150.3M | 6.38M | $23.56 | 3+ qtrs | No change |
| 13 | Tyra Biosciences IncTYRA | — | 1.97% | $147.9M | 10.64M | $13.90 | 3+ qtrs | ▲ Added 2.1% |
| 14 | RxSight IncRXST · SH | — | 1.71% | $128.7M | 3.74M | $34.38 | 3+ qtrs | ▼ Reduced 4.4% |
| 15 | Bicara Therapeutics IncBCAX | — | 1.61% | $121.2M | 6.96M | $17.42 | 2 qtrs | No change |
| 16 | Lenz Therapeutics IncLENZ | — | 1.61% | $120.6M | 4.18M | $28.87 | 3+ qtrs | No change |
| 17 | Ars Pharmaceuticals IncSPRY | — | 1.53% | $114.6M | 10.86M | $10.55 | 3+ qtrs | No change |
| 18 | 89BIO Incno ticker on file · SH | — | 1.48% | $110.9M | 14.18M | $7.82 | 3+ qtrs | No change |
| 19 | SPDR Series TrustXBI · SH | — | 1.47% | $110.6M | 1.23M | $90.06 | 1 qtr | New |
| 20 | Geron CorpGERN | — | 1.41% | $106.2M | 30.01M | $3.54 | 3+ qtrs | ▼ Reduced 7.1% |
| 21 | Artiva Biotherapeutics IncARTV | — | 1.32% | $99.3M | 9.85M | $10.08 | 2 qtrs | No change |
| 22 | Axsome Therapeutics IncAXSM · SH | Health Care | 1.13% | $84.6M | 1M | $84.61 | 3+ qtrs | No change |
| 23 | Verona Pharma Plcno ticker on file · SH | — | 1.09% | $82.1M | 1.77M | $46.44 | 3+ qtrs | ▼ Reduced 65% |
| 24 | Day One Biopharmaceuticalsno ticker on file · SH | — | 0.97% | $72.9M | 5.76M | $12.67 | 3+ qtrs | ▼ Reduced 27% |
| 25 | Apogee Therapeutics Incno ticker on file · SH | — | 0.95% | $71.1M | 1.57M | $45.30 | 3+ qtrs | ▼ Reduced 20% |
| 26 | Mineralys Therapeutics IncMLYS | — | 0.80% | $59.7M | 4.85M | $12.31 | 3+ qtrs | No change |
| 27 | Praxis Precision MedicinesPRAX | Health Care | 0.78% | $58.6M | 761.96K | $76.96 | 3+ qtrs | No change |
| 28 | Climb Bio IncCLYM | — | 0.75% | $56.6M | 31.42M | $1.80 | 3+ qtrs | No change |
| 29 | Recursion Pharmaceuticals IncRXRX · SH | — | 0.70% | $52.2M | 7.73M | $6.76 | 3+ qtrs | ▼ Reduced 50% |
| 30 | Tourmaline Bio Incno ticker on file · SH | — | 0.69% | $51.5M | 2.54M | $20.28 | 3+ qtrs | No change |
| 31 | Acrivon Therapeutics IncACRV | — | 0.67% | $50.2M | 8.34M | $6.02 | 3+ qtrs | No change |
| 32 | Fulcrum Therapeutics IncFULC | — | 0.64% | $48.1M | 10.23M | $4.70 | 3+ qtrs | No change |
| 33 | 10X Genomics IncTXG · SH | Health Care | 0.63% | $47.1M | 3.28M | $14.36 | 1 qtr | New |
| 34 | GH Research PLCGHRS | — | 0.62% | $46.8M | 6.69M | $7.00 | 3+ qtrs | No change |
| 35 | Astria Therapeutics Incno ticker on file · SH | — | 0.61% | $45.6M | 5.11M | $8.94 | 3+ qtrs | No change |
| 36 | Vor Biopharma IncVOR · SH | — | 0.59% | $44M | 39.65M | $1.11 | 3+ qtrs | ▲ Added 74% |
| 37 | Structure Therapeutics IncGPCR · SH | — | 0.55% | $41.2M | 1.52M | $27.12 | 3+ qtrs | ▼ Reduced 20% |
| 38 | Dianthus Therapeutics IncDNTH | Health Care | 0.54% | $40.7M | 1.87M | $21.80 | 3+ qtrs | ▼ Reduced 20% |
| 39 | Pepgen IncPEPG | — | 0.54% | $40.5M | 10.69M | $3.79 | 3+ qtrs | No change |
| 40 | Evolent Health IncEVH · SH | — | 0.54% | $40.2M | 3.58M | $11.25 | 3+ qtrs | ▼ Reduced 58% |
| 41 | Kura Oncology IncKURA · SH | — | 0.52% | $38.8M | 4.45M | $8.71 | 1 qtr | New |
| 42 | IDEAYA Biosciences IncIDYA · SH | — | 0.46% | $34.6M | 1.35M | $25.70 | 2 qtrs | No change |
| 43 | Zai Lab LtdZLAB · ADR | — | 0.45% | $33.9M | 1.3M | $26.19 | 1 qtr | New |
| 44 | Chimerix Incno ticker on file · SH | — | 0.41% | $30.6M | 8.8M | $3.48 | 3+ qtrs | No change |
| 45 | Cidara Therapeutics Incno ticker on file · SH | — | 0.39% | $29.4M | 1.09M | $26.88 | 2 qtrs | ▲ Added 55% |
| 46 | MBX Biosciences IncMBX · SH | — | 0.37% | $27.9M | 1.51M | $18.43 | 2 qtrs | No change |
| 47 | Nkarta IncNKTX | — | 0.36% | $26.9M | 10.81M | $2.49 | 3+ qtrs | No change |
| 48 | Acumen Pharmaceuticals IncABOS | — | 0.34% | $25.7M | 14.93M | $1.72 | 3+ qtrs | No change |
| 49 | 4D Molecular TherapeuticsFDMT | — | 0.34% | $25.4M | 4.56M | $5.57 | 3+ qtrs | ▼ Reduced 10% |
| 50 | Nurix Therapeutics IncNRIX · SH | — | 0.33% | $25.1M | 1.33M | $18.84 | 1 qtr | New |
| 51 | Sera Prognostics IncSERA · SH | — | 0.33% | $24.7M | 3.03M | $8.14 | 3+ qtrs | No change |
| 52 | Aerovate Therapeutics Incno ticker on file · SH | — | 0.32% | $24.4M | 9.19M | $2.65 | 3+ qtrs | No change |
| 53 | Eyepoint Pharmaceuticals IncEYPT · SH | — | 0.32% | $23.7M | 3.18M | $7.45 | 1 qtr | New |
| 54 | Larimar Therapeutics IncLRMR · SH | — | 0.31% | $23.4M | 6.05M | $3.87 | 3+ qtrs | No change |
| 55 | Ceribell IncCBLL · SH | — | 0.28% | $21.3M | 824.58K | $25.88 | 1 qtr | New |
| 56 | Travere Therapeutics IncTVTX | Health Care | 0.27% | $20M | 1.15M | $17.42 | 1 qtr | New |
| 57 | Enliven Therapeutics IncELVN · SH | — | 0.25% | $19.1M | 848.99K | $22.50 | 3+ qtrs | ▼ Reduced 20% |
| 58 | Taysha Gene Therapies IncTSHA | — | 0.25% | $18.8M | 10.87M | $1.73 | 3+ qtrs | No change |
| 59 | Alector IncALEC · SH | — | 0.24% | $18.3M | 9.7M | $1.89 | 1 qtr | New |
| 60 | Protara Therapeutics IncTARA · SH | — | 0.24% | $18M | 3.4M | $5.28 | 3+ qtrs | ▲ Added 79% |
| 61 | C4 Therapeutics IncCCCC | — | 0.23% | $17.6M | 4.88M | $3.60 | 3+ qtrs | No change |
| 62 | Solid Biosciences IncSLDB | — | 0.23% | $17.3M | 4.33M | $4.00 | 3+ qtrs | No change |
| 63 | Pliant Therapeutics IncPLRX · SH | — | 0.23% | $16.9M | 1.28M | $13.17 | 3+ qtrs | No change |
| 64 | Bright Minds Biosciences IncDRUG | — | 0.22% | $16.6M | 460.83K | $36.02 | 1 qtr | New |
| 65 | Iteos Therapeutics Incno ticker on file · SH | — | 0.21% | $16.1M | 2.09M | $7.68 | 3+ qtrs | ▼ Reduced 34% |
| 66 | Bicycle Therapeutics PlcBCYC · SH | — | 0.20% | $15.3M | 1.09M | $14.00 | 3+ qtrs | ▼ Reduced 51% |
| 67 | Eledon Pharmaceuticals IncELDN · SH | — | 0.20% | $14.7M | 3.57M | $4.12 | 1 qtr | New |
| 68 | Insmed IncINSM · SH | Health Care | 0.18% | $13.8M | 200K | $69.04 | 3+ qtrs | No change |
| 69 | Xencor IncXNCR | — | 0.18% | $13.2M | 575K | $22.98 | 2 qtrs | No change |
| 70 | Immatics N.V.IMTX · SH | — | 0.17% | $12.4M | 1.75M | $7.11 | 3+ qtrs | No change |
| 71 | Aclaris Therapeutics IncACRS | — | 0.15% | $11.6M | 4.67M | $2.48 | 1 qtr | New |
| 72 | Monopar Therapeutics IncMNPR | — | 0.15% | $11.2M | 511.21K | $22.00 | 1 qtr | New |
| 73 | Third Harmonic Bio Incno ticker on file · SH | — | 0.13% | $9.9M | 960.62K | $10.29 | 3+ qtrs | ▼ Reduced 25% |
| 74 | Werewolf Therapeutics IncHOWL | — | 0.12% | $9.1M | 6.14M | $1.48 | 3+ qtrs | No change |
| 75 | Arvinas IncARVN · SH | — | 0.11% | $8.1M | 421.35K | $19.17 | 3+ qtrs | No change |
| 76 | Zura Bio LtdZURA · SH | — | 0.11% | $8M | 3.22M | $2.50 | 3+ qtrs | No change |
| 77 | Perceptive Cap Solutionsno ticker on file | — | 0.10% | $7.6M | 750K | $10.18 | 3+ qtrs | No change |
| 78 | Bioage Labs IncBIOA | — | 0.10% | $7.6M | 1.31M | $5.79 | 2 qtrs | ▼ Reduced 41% |
| 79 | Adicet Bio IncACET · SH | — | 0.10% | $7.3M | 7.54M | $0.9620 | 3+ qtrs | No change |
| 80 | Avalo Therapeutics IncAVTX | — | 0.10% | $7.2M | 967K | $7.43 | 2 qtrs | No change |
| 81 | Boundless Bio IncBOLD · SH | — | 0.08% | $6.3M | 2.18M | $2.90 | 3+ qtrs | No change |
| 82 | Enanta Pharmaceuticals IncENTA · SH | — | 0.08% | $6M | 1.04M | $5.75 | 1 qtr | New |
| 83 | Newamsterdam Pharma Co NV-27no ticker on file · WTS | — | 0.06% | $4.7M | 333.33K | $14.25 | 3+ qtrs | No change |
| 84 | Surrozen IncSRZN · SH | — | 0.05% | $4.1M | 282.58K | $14.35 | 3+ qtrs | No change |
| 85 | Lexeo Therapeutics IncLXEO | — | 0.05% | $3.6M | 546.55K | $6.58 | 3+ qtrs | No change |
| 86 | Allakos Incno ticker on file · SH | — | 0.02% | $1.4M | 1.13M | $1.21 | 1 qtr | New |
| 87 | Scholar Rock Holding CorpSRRK · SH | Health Care | 0.01% | $761.4K | 17.62K | $43.22 | 1 qtr | New |
| 88 | Regulus Therapeutics Incno ticker on file · SH | — | 0.01% | $532.2K | 336.84K | $1.58 | 3+ qtrs | ▼ Reduced 56% |
| 89 | Scilex Holding Cono ticker on file · SH | — | 0.01% | $441.8K | 1.04M | $0.4264 | 3+ qtrs | ▲ Added 297% |
By sector
| Sector | Share of portfolio | Value | Positions |
|---|---|---|---|
| Health Care | 42.5% | $3.2B | 12 |
| No sector on file | 57.5% | $4.3B | 77 |
Questions and answers
What did Peter Kolchinsky own in Q4 2024?
RA Capital Management's 13F for Q4 2024 lists 89 positions worth $7.5B. The largest: ASND (18.5%), PCVX (9.5%), JANX (7.4%), RYTM (4.5%), LEGN (3.3%).
What did Peter Kolchinsky buy in Q4 2024?
The largest purchases, by the shares bought at the quarter-end price the filing implies: SEPN (new, $160.2M), XBI (new, $110.6M), Arcellx Inc (added, $71.8M), JANX (added, $64.2M), ASND (added, $55.4M), TXG (new, $47.1M).
What did Peter Kolchinsky sell in Q4 2024?
The largest sales: BIIB (sold out, $229.6M), Verona Pharma Plc (reduced, $150.6M), EVH (reduced, $55.5M), CGON (sold out, $52.7M), RXRX (reduced, $51.8M), Day One Biopharmaceuticals (reduced, $26.8M).
When was this filing made?
RA Capital Management filed its 13F for the quarter ending Dec 31, 2024 on Feb 14, 2025. A 13F is due within 45 days of the quarter's end, so the positions were already weeks old when it became public.
Learn
Cite this page
Funkfolio, “Peter Kolchinsky portfolio, Q4 2024: RA Capital Management 13F holdings”, data as of 14 February 2025. https://funkfolio.com/gurus/peter-kolchinsky/2024-q4
Underlying data: SEC EDGAR, Form 13F-HR of RA Capital Management (CIK 1346824) for the period ending Dec 31, 2024.
Source: SEC EDGAR, Form 13F-HR for RA Capital Management (CIK 1346824), period ending Dec 31, 2024, filed Feb 14, 2025. Changes compare share counts with the filing for Sep 30, 2024; a share split in between is allowed for where one is on record. “Reported price” is a position's reported value divided by its shares. The size of a buy or sell is the change in shares at that price; a position sold out is sized at its value in the previous filing, and “of portfolio” sets the size against the $7.5B reported for this quarter. “Held” counts consecutive quarterly filings up to this one, out of the 3 looked at from here back. Sectors are those of the ranked companies on this site as they stand today. Not a live portfolio and not advice.